{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:56:25Z","timestamp":1788389785160,"version":"build-2803163510"},"reference-count":114,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Glioblastoma multiforme (GBM), the most aggressive primary brain tumor in adults, has a poor prognosis due to rapid recurrence and treatment resistance. This review examines the evolution of radiotherapy (RT) for GBM management, from whole-brain RT to modern techniques like intensity-modulated RT (IMRT) and volumetric modulated arc therapy (VMAT), guided by 2023 European Society for Radiotherapy and Oncology (ESTRO)-European Association of Neuro-Oncology (EANO) and 2025 American Society for Radiation Oncology (ASTRO) recommendations. The standard Stupp protocol (60 Gy\/30 fractions with temozolomide [TMZ]) improves overall survival (OS) to 14.6 months, with greater benefits in O6-methylguanine-DNA methyltransferase (MGMT)-methylated tumors (21.7 months). Tumor Treating Fields (TTFields) extend median overall survival (mOS) to 31.6 months in MGMT-methylated patients and 20.9 months overall in supratentorial GBM (EF-14 trial). However, 80\u201390% of recurrences occur within 2 cm of the irradiated field due to tumor infiltration and radioresistance driven by epidermal growth factor receptor (EGFR) amplification, phosphatase and tensin homolog (PTEN) mutations, cyclin-dependent kinase inhibitor 2A\/B (CDKN2A\/B) deletions, tumor hypoxia, and tumor stem cells. Pseudoprogression, distinguished using Response Assessment in Neuro-Oncology (RANO) criteria and positron emission tomography (PET), complicates response evaluation. Targeted therapies (e.g., bevacizumab; PARP inhibitors) and immunotherapies (e.g., pembrolizumab; oncolytic viruses), alongside advanced imaging (multiparametric magnetic resonance imaging [MRI], amino acid PET), support personalized RT. Ongoing trials evaluating reirradiation, hypofractionation, stereotactic radiosurgery, neoadjuvant therapies, proton therapy (PT), boron neutron capture therapy (BNCT), and AI-driven planning aim to enhance efficacy for GBM IDH-wildtype, but phase III trials are needed to improve survival and quality of life.<\/jats:p>","DOI":"10.3390\/biomedicines13092136","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T13:27:44Z","timestamp":1756733264000},"page":"2136","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6005-3521","authenticated-orcid":false,"given":"Castalia","family":"Fern\u00e1ndez","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0130-878X","authenticated-orcid":false,"given":"Raquel","family":"Ci\u00e9rvide","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario HM Sanchinarro, HM Hospitales, 28050 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8453-5971","authenticated-orcid":false,"given":"Ana","family":"D\u00edaz","sequence":"additional","affiliation":[{"name":"Radiation Therapy Department, Quironsalud Madrid University Hospital, Diego de Vel\u00e1zquez 1, Pozuelo de Alarc\u00f3n, 28223 Madrid, Spain"},{"name":"Department of Medicine, Health and Sports, European University of Madrid, Villaviciosa de Od\u00f3n, 28670 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Garrido","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7233-0234","authenticated-orcid":false,"given":"Felipe","family":"Cou\u00f1ago","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Hospital Universitario San Francisco de As\u00eds, GenesisCare, 28002 Madrid, Spain"},{"name":"Department of Radiation Oncology, Hospital Universitario Vithas La Milagrosa, GenesisCare, 28010 Madrid, Spain"},{"name":"Department of Medicine, Health and Sports, European University of Madrid, Villaviciosa de Od\u00f3n, 28670 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/now207","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009\u20132013","volume":"18","author":"Ostrom","year":"2016","journal-title":"Neuro-Oncology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1007\/s12094-023-03245-y","article-title":"SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)","volume":"25","author":"Segura","year":"2023","journal-title":"Clin. Transl. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jama.2023.8590","article-title":"A review of glioblastoma and other primary brain malignancies\u2014Reply","volume":"330","author":"Schaff","year":"2023","journal-title":"JAMA"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1093\/neuonc\/noab076","article-title":"The incidence of major subtypes of primary brain tumors in adults in England 1995\u20132017","volume":"23","author":"Wanis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Brown, N.F., Ottaviani, D., Tazare, J., Gregson, J., Kitchen, N., Brandner, S., Fersht, N., and Mulholland, P. (2022). Survival outcomes and prognostic factors in glioblastoma. Cancers, 14.","DOI":"10.3390\/cancers14133161"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(07)70384-4","article-title":"Nomograms for predicting survival of patients with newly diagnosed glioblastoma: Prognostic factor analysis of EORTC and NCIC trial 26981-22981\/CE.3","volume":"9","author":"Gorlia","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Sipos, D., Raposa, B.L., Freihat, O., Simon, M., Mekis, N., Cornacchione, P., and Kov\u00e1cs, \u00c1. (2025). Glioblastoma: Clinical presentation, multidisciplinary management, and long-term outcomes. Cancers, 17.","DOI":"10.3390\/cancers17010146"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3171\/2024.5.JNS24393","article-title":"Long-term survivors in 976 supratentorial glioblastoma, IDH-wildtype patients","volume":"142","author":"Aboubakr","year":"2025","journal-title":"J. Neurosurg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/curroncol32040207","article-title":"Canadian expert consensus recommendations for the diagnosis and management of glioblastoma: Results of a Delphi study","volume":"32","author":"Mason","year":"2025","journal-title":"Curr. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.prro.2025.05.014","article-title":"Radiation therapy for WHO grade 4 adult-type diffuse glioma: An ASTRO clinical practice guideline","volume":"15","author":"Yeboa","year":"2025","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO.2016.70.7562","article-title":"Radiation therapy for glioblastoma: American Society of Clinical Oncology clinical practice guideline endorsement of the American Society for Radiation Oncology guideline","volume":"35","author":"Sulman","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.prro.2016.03.007","article-title":"Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology evidence-based clinical practice guideline","volume":"6","author":"Cabrera","year":"2016","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1093\/neuonc\/noaa107","article-title":"A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)","volume":"22","author":"Balana","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: A randomized clinical trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"ref_17","first-page":"153","article-title":"Radiotherapeutic approaches in the treatment of adult gliomas","volume":"163","author":"Roubil","year":"2025","journal-title":"Adv. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1611977","article-title":"Short-course radiation plus temozolomide in elderly patients with glioblastoma","volume":"376","author":"Perry","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1200\/JCO.2004.06.082","article-title":"Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: A prospective randomized clinical trial","volume":"22","author":"Roa","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1200\/JCO.2015.62.6606","article-title":"International Atomic Energy Agency randomized phase III study of radiation therapy in elderly and\/or frail patients with newly diagnosed glioblastoma multiforme","volume":"33","author":"Roa","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s11060-008-9689-z","article-title":"Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma","volume":"91","author":"Minniti","year":"2009","journal-title":"J. Neurooncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1470-2045(12)70265-6","article-title":"Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: The Nordic randomised, phase 3 trial","volume":"13","author":"Marosi","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"de Melo, S.M., Marta, G.N., de Latorraca, C.O.C., Martins, C.B., Efthimiou, O., and Riera, R. (2021). Hypofractionated radiotherapy for newly diagnosed elderly glioblastoma patients: A systematic review and network meta-analysis. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0257384"},{"key":"ref_24","first-page":"CD013261","article-title":"Treatment of newly diagnosed glioblastoma in the elderly: A network meta-analysis","volume":"3","author":"Hanna","year":"2020","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109663","DOI":"10.1016\/j.radonc.2023.109663","article-title":"ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma","volume":"184","author":"Niyazi","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.radonc.2015.12.003","article-title":"ESTRO-ACROP Guideline \u201cTarget Delineation of Glioblastomas\u201d","volume":"118","author":"Niyazi","year":"2016","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/nop\/npz024","article-title":"Impact of Volume of Irradiation on Survival and Quality of Life in Glioblastoma: A Prospective, Phase 2, Randomized Comparison of RTOG and MDACC Protocols","volume":"7","author":"Kumar","year":"2020","journal-title":"Neuro-Oncology. Pract."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.radonc.2010.08.020","article-title":"Patterns of Failure and Comparison of Different Target Volume Delineations in Patients with Glioblastoma Treated with Conformal Radiotherapy plus Concomitant and Adjuvant Temozolomide","volume":"97","author":"Minniti","year":"2010","journal-title":"Radiother. Oncol. J. Eur. Soc. Ther. Radiol. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijrobp.2006.12.009","article-title":"Evaluation of Peritumoral Edema in the Delineation of Radiotherapy Clinical Target Volumes for Glioblastoma","volume":"68","author":"Chang","year":"2007","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.ijrobp.2024.11.073","article-title":"Contouring with FLAIR: Targeting Peritumoral Edema (and Beyond) in Glioblastoma","volume":"121","author":"Karp","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.ijrobp.2024.11.094","article-title":"Toxicity and Efficacy of Different Target Volume Delineations of Radiation Therapy Based on the Updated Radiation Therapy Oncology Group\/National Research Group and European Organization for Research and Treatment of Cancer Guidelines in Patients with Glioma","volume":"121","author":"Qiu","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0360-3016(89)90941-3","article-title":"Patterns of Failure Following Treatment for Glioblastoma Multiforme and Anaplastic Astrocytoma","volume":"16","author":"Wallner","year":"1989","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jocn.2021.05.002","article-title":"The Survival Impact of Significant Delays between Surgery and Radiochemotherapy in Glioblastoma Patients: A Retrospective Analysis from a Large Tertiary Center","volume":"90","author":"Magrowski","year":"2021","journal-title":"J. Clin. Neurosci."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.21037\/tcr-20-1718","article-title":"Survival Impact of Delaying Postoperative Chemoradiotherapy in Newly Diagnosed Glioblastoma Patients","volume":"9","author":"Zhang","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"104110","DOI":"10.1016\/j.critrevonc.2023.104110","article-title":"Radiotherapy of High-Grade Gliomas: Dealing with a Stalemate","volume":"190","author":"Frosina","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101465","DOI":"10.1016\/j.adro.2024.101465","article-title":"Review of recent improvements in carbon ion radiation therapy in the treatment of glioblastoma","volume":"9","author":"Koosha","year":"2024","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Kunikowska, J., Morgenstern, A., Pe\u0142ka, K., Bruchertseifer, F., and Kr\u00f3licki, L. (2022). Targeted alpha therapy for glioblastoma. Front. Med., 9.","DOI":"10.3389\/fmed.2022.1085245"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/neuonc\/noab111","article-title":"A Randomized Phase II Trial of Veliparib, Radiotherapy, and Temozolomide in Patients with Unmethylated MGMT Glioblastoma: The VERTU Study","volume":"23","author":"Sim","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The Somatic Genomic Landscape of Glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1200\/JCO.2008.17.5984","article-title":"Randomized Phase II Trial of Erlotinib versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034","volume":"27","author":"Brandes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Matarredona, E.R., and Pastor, A.M. (2019). Neural Stem Cells of the Subventricular Zone as the Origin of Human Glioblastoma Stem Cells: Therapeutic Implications. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00779"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.4103\/jcrt.JCRT_295_17","article-title":"Impact of Subventricular Zone Irradiation on Outcome of Patients with Glioblastoma","volume":"14","author":"Mathew","year":"2018","journal-title":"J. Cancer Res. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1093\/neuonc\/noaa182","article-title":"Proton Therapy Reduces the Likelihood of High-Grade Radiation-Induced Lymphopenia in Glioblastoma Patients: Phase II Randomized Study of Protons vs Photons","volume":"23","author":"Mohan","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref_45","first-page":"1411","article-title":"Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions","volume":"27","author":"Wen","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1200\/JCO.2007.14.8163","article-title":"MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression after Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients","volume":"26","author":"Brandes","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1200\/JCO.23.01059","article-title":"RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults","volume":"41","author":"Wen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/neuonc\/noad187","article-title":"Integrating Multi-Modal Imaging in Radiation Treatments for Glioblastoma","volume":"26","author":"Breen","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_49","first-page":"299","article-title":"Management of Glioblastoma: State of the Art and Future Directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ma, Y., Wang, Y., Nie, C., and Lin, Y. (2023). The Efficacy of Targeted Therapy Combined with Radiotherapy and Temozolomide-Based Chemotherapy in the Treatment of Glioma: A Systemic Review and Meta-Analysis of Phase II\/III Randomized Controlled Trials. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1082539"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/nrneurol.2009.197","article-title":"MGMT Promoter Methylation in Malignant Gliomas: Ready for Personalized Medicine?","volume":"6","author":"Weller","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","article-title":"Phase I\/II Trial of Erlotinib and Temozolomide with Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177","volume":"26","author":"Brown","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/neuonc\/noaa106","article-title":"Glioblastoma in adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions","volume":"22","author":"Wen","year":"2020","journal-title":"Neuro Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"vdaa126","DOI":"10.1093\/noajnl\/vdaa126","article-title":"Prognostic impact of CDKN2A\/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma","volume":"2","author":"Ma","year":"2020","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41586-019-1775-1","article-title":"Longitudinal molecular trajectories of diffuse glioma in adults","volume":"576","author":"Barthel","year":"2019","journal-title":"Nature"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/neuonc\/noae213","article-title":"Updated EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection-update 1","volume":"27","author":"Franceschi","year":"2025","journal-title":"Neuro Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.ijrobp.2008.07.031","article-title":"Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-ribose) polymerase: Mechanisms and therapeutic potential","volume":"72","author":"Dungey","year":"2008","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/OP.22.00476","article-title":"Key clinical principles in the management of glioblastoma","volume":"19","author":"Kotecha","year":"2023","journal-title":"JCO Oncol. Pract."},{"key":"ref_61","first-page":"858","article-title":"Current state of proton therapy for tumors of the central nervous system in Spain: Physical bases, indications, controversies and perspectives","volume":"27","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/neuonc\/noab040","article-title":"A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma","volume":"23","author":"Brown","year":"2021","journal-title":"Neuro Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.ijrobp.2020.07.2109","article-title":"Radiotherapy (RT) dose-intensification (DI) using intensity-modulated RT (IMRT) versus standard-dose (SD) RT with temozolomide (TMZ) in newly diagnosed glioblastoma (GBM): Preliminary results of NRG Oncology BN001","volume":"108","author":"Gondi","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"46","DOI":"10.21037\/cco-22-92","article-title":"Proton radiotherapy for glioma and glioblastoma","volume":"11","author":"Goff","year":"2022","journal-title":"Chin. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"vdab067","DOI":"10.1093\/noajnl\/vdab067","article-title":"Accelerator-based BNCT for patients with recurrent glioblastoma: A multicenter phase II study","volume":"3","author":"Kawabata","year":"2021","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_66","first-page":"e33898","article-title":"Boron neutron capture therapy for recurrent glioblastoma multiforme: Imaging evaluation of a case with long-term local control and survival","volume":"15","author":"Shimizu","year":"2023","journal-title":"Cureus"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Ocanto, A., Torres, L., Montijano, M., Rinc\u00f3n, D., Fern\u00e1ndez, C., Sevilla, B., Gonsalves, D., Teja, M., Guijarro, M., and Glar\u00eda, L. (2024). MR-LINAC, a new partner in radiation oncology: Current landscape. Cancers, 16.","DOI":"10.3390\/cancers16020270"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Detsky, J., Chan, A.W., Palhares, D.M., Hudson, J.M., Stewart, J., Chen, H., Das, S., Lipsman, N., Lim-Fat, M.J., and Perry, J. (2024). MR-Linac on-line weekly adaptive radiotherapy for high grade glioma (HGG): Results from the UNITED single arm phase II trial. Int. J. Radiat. Oncol. Biol. Phys., 120.","DOI":"10.1016\/j.ijrobp.2024.08.016"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11060-023-04348-w","article-title":"Association of tumor treating fields (TTFields) therapy with survival in newly diagnosed glioblastoma: A systematic review and meta-analysis","volume":"164","author":"Ballo","year":"2023","journal-title":"J. Neurooncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"oyae227","DOI":"10.1093\/oncolo\/oyae227","article-title":"Recent advances in tumor treating fields (TTFields) therapy for glioblastoma","volume":"30","author":"Khagi","year":"2025","journal-title":"Oncologist"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/s41416-020-01136-5","article-title":"Tumour treating fields therapy for glioblastoma: Current advances and future directions","volume":"124","author":"Rominiyi","year":"2021","journal-title":"Br. J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Szasz, A.M., Arrojo Alvarez, E.E., Fiorentini, G., Herold, M., Herold, Z., Sarti, D., and Dank, M. (2023). Meta-analysis of modulated electro-hyperthermia and tumor treating fields in the treatment of glioblastomas. Cancers, 15.","DOI":"10.3390\/cancers15030880"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e017387","DOI":"10.1136\/bmjopen-2017-017387","article-title":"Clinical and economic evaluation of modulated electrohyperthermia concurrent to dose-dense temozolomide 21\/28 days regimen in the treatment of recurrent glioblastoma: A retrospective analysis of a two-centre German cohort trial with systematic comparison","volume":"7","author":"Roussakow","year":"2017","journal-title":"BMJ Open"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Lee, S.Y., Lorant, G., Grand, L., and Szasz, A.M. (2023). The clinical validation of modulated electro-hyperthermia (mEHT). Cancers, 15.","DOI":"10.3390\/cancers15184569"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3892\/ol.2024.14573","article-title":"Local therapy in glioma: An evolving paradigm from history to horizons (review)","volume":"28","author":"Ius","year":"2024","journal-title":"Oncol. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11060-023-04391-7","article-title":"Hypo-fractionated accelerated radiotherapy with concurrent and maintenance temozolomide in newly diagnosed glioblastoma: Updated results from phase II HART-GBM trial","volume":"164","author":"Mallick","year":"2023","journal-title":"J. Neurooncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11060-022-04151-z","article-title":"Moderately hypofractionated versus conventionally fractionated radiation therapy with temozolomide for young and fit patients with glioblastoma: An institutional experience and meta-analysis of literature","volume":"160","author":"Chidley","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.canrad.2020.08.049","article-title":"The efficacy of hypofractionated radiotherapy (HFRT) with concurrent and adjuvant temozolomide in newly diagnosed glioblastoma: A meta-analysis","volume":"25","author":"Guo","year":"2021","journal-title":"Cancer Radiother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11060-021-03926-0","article-title":"Accelerated hyper-versus normofractionated radiochemotherapy with temozolomide in patients with glioblastoma: A multicenter retrospective analysis","volume":"156","author":"Klement","year":"2022","journal-title":"J. Neurooncol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Liao, G., Zhao, Z., Yang, H., and Li, X. (2019). Efficacy and safety of hypofractionated radiotherapy for the treatment of newly diagnosed glioblastoma multiforme: A systematic review and meta-analysis. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.01017"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ijrobp.2021.05.001","article-title":"Dose escalated radiation therapy for glioblastoma multiforme: An international systematic review and meta-analysis of 22 prospective trials","volume":"111","author":"Singh","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"110696","DOI":"10.1016\/j.radonc.2024.110696","article-title":"ESTRO\/EANO recommendation on reirradiation of glioblastoma","volume":"204","author":"Andratschke","year":"2025","journal-title":"Radiother. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Lo Greco, M.C., Milazzotto, R., Liardo, R.L.E., Acquaviva, G., La Rocca, M., Altieri, R., Certo, F., Barbagallo, G.M., Basile, A., and Foti, P.V. (2022). Relapsing high-grade glioma from peritumoral zone: Critical review of radiotherapy treatment options. Brain Sci., 12.","DOI":"10.3390\/brainsci12040416"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13063-024-08213-7","article-title":"Lomustine with or without reirradiation for first progression of glioblastoma, LEGATO, EORTC-2227-BTG: Study protocol for a randomized phase III study","volume":"25","author":"Preusser","year":"2024","journal-title":"Trials"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.ijrobp.2024.01.013","article-title":"Prospective randomized phase 2 trial of hypofractionated stereotactic radiation therapy of 25 Gy in 5 fractions compared with 35 Gy in 5 fractions in the reirradiation of recurrent glioblastoma","volume":"119","author":"Chen","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"vdae028","DOI":"10.1093\/noajnl\/vdae028","article-title":"State of the neoadjuvant therapy for glioblastoma multiforme\u2014Where do we stand?","volume":"6","author":"Nabian","year":"2024","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_87","first-page":"ii29","article-title":"STMO-15 Our therapeutic strategies for glioblastoma: Intraoperative support systems [intraoperative MRI, PET, 5-aminolevulinic acid (5-ALA)] and neoadjuvant chemotherapy","volume":"1","author":"Miyake","year":"2019","journal-title":"Neuro-Oncol. Adv."},{"key":"ref_88","first-page":"100585","article-title":"Study protocol: Preoperative brain irradiation in glioblastoma (POBIG)\u2014A phase I trial","volume":"39","author":"Waqar","year":"2023","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1159\/000343139","article-title":"Upfront bevacizumab and temozolomide or fotemustine before radiotherapy for patients with glioblastoma and severe neurological impairment at diagnosis","volume":"5","author":"Bihan","year":"2012","journal-title":"Case Rep. Oncol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11060-016-2065-5","article-title":"Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: The GENOM 009 randomized phase II trial","volume":"127","author":"Balana","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s11060-019-03211-1","article-title":"Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: A retrospective cohort study","volume":"144","author":"Jiang","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Sun, Y., Wang, Y., Mu, S., Wu, X., Yu, S., and Wang, Z. (2025). Combining immunotherapy with radiotherapy for glioblastoma: Recent advances and challenges. Front. Oncol., 15.","DOI":"10.3389\/fonc.2025.1523675"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41591-025-03512-1","article-title":"Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma","volume":"31","author":"Long","year":"2025","journal-title":"Nat. Med."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Baskaran, A.B., Kozel, O.A., Venkatesh, O., Wainwright, D.A., Sonabend, A.M., Heimberger, A.B., and Lukas, R.V. (2024). Immune checkpoint inhibitors in glioblastoma IDHwt treatment: A systematic review. Cancers, 16.","DOI":"10.3390\/cancers16244148"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1200\/JCO.2013.49.6067","article-title":"Net clinical benefit analysis of Radiation Therapy Oncology Group 0525: A phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma","volume":"31","author":"Armstrong","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): A randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s11060-010-0403-6","article-title":"Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy","volume":"103","author":"Reardon","year":"2011","journal-title":"J. Neurooncol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and bevacizumab in progressive glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Cruz Da Silva, E., Mercier, M.-C., Etienne-Selloum, N., Dontenwill, M., and Choulier, L. (2021). A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers, 13.","DOI":"10.3390\/cancers13081795"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa1308345","article-title":"Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma","volume":"370","author":"Chinot","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S1470-2045(14)70379-1","article-title":"Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial","volume":"15","author":"Stupp","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"TPS2096","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS2096","article-title":"A global phase 3, open-label, randomized 2-arm study comparing the clinical efficacy and safety of niraparib with temozolomide in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma","volume":"43","author":"Sanai","year":"2025","journal-title":"J. Clin Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"10757","DOI":"10.1038\/s41467-024-54326-7","article-title":"Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: Clinical and molecular outcomes of a stage 2 single-arm expansion cohort","volume":"15","author":"Sun","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/s41591-023-02347-y","article-title":"Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: A phase 1\/2 trial","volume":"29","author":"Nassiri","year":"2023","journal-title":"Nat. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Martucci, M., Russo, R., Giordano, C., Schiarelli, C., D\u2019Apolito, G., Tuzza, L., Lisi, F., Ferrara, G., Schimperna, F., and Vassalli, S. (2023). Advanced magnetic resonance imaging in the evaluation of treated glioblastoma: A pictorial essay. Cancers, 15.","DOI":"10.3390\/cancers15153790"},{"key":"ref_108","first-page":"101621","article-title":"RANO-2.0: Update to the response assessment for gliomas","volume":"41","author":"Pineda","year":"2024","journal-title":"Radiologia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4103\/jrms.JRMS_1138_20","article-title":"Determining the Optimum Tumor Control Probability Model in Radiotherapy of Glioblastoma Multiforme Using Magnetic Resonance Imaging Data Pre- and Post-Radiation Therapy","volume":"27","author":"Banisharif","year":"2022","journal-title":"J. Res. Med. Sci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1016\/S1470-2045(23)00525-9","article-title":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): A report of the RANO group","volume":"25","author":"Albert","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"S185","DOI":"10.1093\/neuonc\/noae078","article-title":"PET imaging of gliomas: Status quo and quo vadis?","volume":"26","author":"Galldiks","year":"2024","journal-title":"Neuro Oncol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/curroncol28060444","article-title":"Feasibility on the use of radiomics features of 11[C]-MET PET\/CT in central nervous system tumours: Preliminary results on potential grading discrimination using a machine learning model","volume":"28","author":"Russo","year":"2021","journal-title":"Curr. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e559","DOI":"10.1097\/RLU.0000000000004903","article-title":"68 Ga-PSMA-11 PET\/CT imaging in brain gliomas and its correlation with clinicopathological prognostic parameters","volume":"48","author":"Verma","year":"2023","journal-title":"Clin. Nucl. Med."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Zhu, M., Li, S., Kuang, Y., Hill, D.L., Tscheikner, M.E., Alnawaf, H., Koh, E.-S., Malycha, P., McLean, M., and Penniment, M. (2022). Artificial Intelligence in the Radiomic Analysis of Glioblastomas: A Review, Taxonomy, and Perspective. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.924245"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/9\/2136\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:37:12Z","timestamp":1760035032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/13\/9\/2136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":114,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["biomedicines13092136"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines13092136","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]}}}